Huakang Biomedical Holdings Co (HKSE:08622) Change In Working Capital : HK$0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Huakang Biomedical Holdings Co Change In Working Capital?

Huakang Biomedical Holdings Co's change in working capital for the quarter that ended in Dec. 2024 was HK$0.00 Mil.

Huakang Biomedical Holdings Co's change in working capital for the fiscal year that ended in Dec. 2024 was HK$-1.89 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Huakang Biomedical Holdings Co Change In Working Capital Historical Data

The historical data trend for Huakang Biomedical Holdings Co's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huakang Biomedical Holdings Co Change In Working Capital Chart

Huakang Biomedical Holdings Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Working Capital

Get a 7-Day Free Trial

-0.94

-1.82

1.76

0.82

-1.89

Huakang Biomedical Holdings Co Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Dec24
Change In Working Capital	Get a 7-Day Free Trial															-	-	-	-	-

Huakang Biomedical Holdings Co Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0.00 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Huakang Biomedical Holdings Co Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Huakang Biomedical Holdings Co's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Huakang Biomedical Holdings Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huakang Biomedical Holdings Co Ltd (HKSE:08622) » Definitions » Change In Working Capital

Traded in Other Exchanges

N/A

Address

No.16 Yinkui Road, 1-3 floor and 5th floor, Building D, Shenzhen Junxuan, Kui Xin Community, Kui Chong Office, Dapeng New District, Shenzhen, CHN

Website

https://www.szhuakang.com

Huakang Biomedical Holdings Co Ltd is engaged in the research, development, manufacture, marketing, and sale of in-vitro diagnostic reagents and auxiliary reproductive supplies and equipment in China. Its products include Male fertility IVD reagents; Parasite antibody detection reagents, EBV antibody detection reagents, and Auxiliary reproductive supplies and equipment. The group has also diversified its business to vitamins and supplements products for the markets in the PRC, Hong Kong, and Canada. The company derives maximum revenue from PRC.

Executives

Yu Chi Mau	2106 Person having a security interest in shares
Li King Yeung	2106 Person having a security interest in shares
Crystal Grant Limited	2101 Beneficial owner
Arena Investment Management (singapore) Pte Ltd	2102 Investment manager
Arena Investors, Lp	2102 Investment manager
Arena Sg Spv I, Llc	2201 Interest of corporation controlled by you
Tgga, Llc	2106 Person having a security interest in shares
Lau Lai Yee	2201 Interest of corporation controlled by you
Kokusai Resources Company Limited	2101 Beneficial owner
Zhang Shuguang	2101 Beneficial owner
Chang Yim Yang	2401 A concert party to an agreement to buy shares
Ever Charming Inc.	2101 Beneficial owner
Wealthy Pride Investment Limited	2101 Beneficial owner

Huakang Biomedical Holdings Co Headlines

No Headlines